Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The therapeutic effect of chemotherapy is still unclear for clinical usage among second primary non‐small cell lung cancer (NSCLC) patients. The aim of this study was to verify the therapeutic effect of chemotherapy and identify the prognostic factors among patients who had received chemotherapy for second primary NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A retrospective cohort was constructed based on the Surveillance, Epidemiology and End Results (SEER) database. Through least absolute shrinkage and selection operator regression, univariate Cox and multivariate Cox regression, we identified the prognostic factors among clinicopathological features. Propensity score matching analysis was used to verify the therapeutic effect of chemotherapy. Survival curves were plotted among the subgroups of the selected factors. We further selected clinicopathological features that would affect the prognosis among patients who had received chemotherapy through a similar process.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 769 patients were enrolled to verify the therapeutic value of chemotherapy for second primary lung cancer. Significant differences were observed between the chemotherapy and nonchemotherapy group for cancer‐specific survival. 215 patients who had received chemotherapy were analyzed to identify the factors that might influence outcome on the therapeutic effect of chemotherapy. Age, tumor size, histology and treatment were selected as significant factors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The therapeutic effect of chemotherapy for second primary NSCLC was found to be significant. Age, tumor size and histology were significant prognostic factors among patients who had received chemotherapy for second primary NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3><b>Significant findings of the study</b><ul class="unordered-list"><li>A significant therapeutic effect of chemotherapy for second primary non‐small cell lung cancer was proven through univariate Cox regression and propensity score matching analysis.</li><li>Prognostic factors for second primary non‐small cell lung cancer patients who had received chemotherapy.</li></ul><b>What this study adds</b><ul class="unordered-list"><li>Chemotherapy could be applied in clinical practice as an additional therapeutic method for second primary non‐small cell lung cancer patients.</li><li>We selected prognostic factors for patients who had received chemotherapy to identify patients who were appropriate for chemotherapy.</li></ul></section>

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

P1.17-001 the Optimal First-Line Treatment for Advanced Thymic Carcinomas

Could S-1-based Non-Platinum Doublet Chemotherapy Be a New Option As a Second-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients? A Multicenter Retrospective Study.

Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis

Efficacy of Different Monotherapies in Second-Line Treatment for Small Cell Lung Cancer: a Meta-Analysis of Randomized Controlled Trials.

Thymoma. A retrospective study of 87 cases

Combined with oxaliplatin or cisplatin in second line treatment of advanced non-small cell lung cancer

Immunotherapy Combined with Chemotherapy Versus Chemotherapy Alone As the First‐line Treatment of PD‐L1‐negative and Driver‐gene‐negative Advanced Nonsquamous Non‐small‐cell Lung Cancer: an Updated Systematic Review and Meta‐analysis

Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations

Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma.

Irinotecan, Topotecan, Paclitaxel or Docetaxel for Second-Line Treatment of Small Cell Lung Cancer: a Single-Center Retrospective Study of Efficiency Comparation and Prognosis Analysis.

Comprehensive Genomic Profiling of 443 Patients with Advanced Renal Cell Carcinoma (rcc) to Reveal Clinically Relevant Genomic Alterations and to Aid in Classification of Rare Subtypes.

Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study

Efficacy and Toxicities of Gemcitabine and Cisplatin Combined with Endostar in Advanced Thymoma and Thymic Carcinoma

Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens

Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study

First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view

Role of chemotherapy for survival in patients with second primary non‐small cell lung cancer

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study

The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study

The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer